Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347904 | 0.83 | MAOB (0.62) | RAB9AMAOBMAOAALOX5 | |
| SCHEMBL23327746 | 0.78 | MAOB (0.69) | NPC1RAB9AMAOBMAOAFFAR1 | |
| SCHEMBL29795224 | 0.78 | MAOB (0.69) | NPC1RAB9AMAOBMAOAFFAR1 | |
| SCHEMBL16801286 | 0.77 | NPC1 (0.47) | NPC1RAB9AMAOBMAOAFFAR1 | |
| Bromide SCHEMBL28842080 | 0.77 | MAOB (0.67) | NPC1RAB9AMAOBMAOAFFAR1 | |
| SCHEMBL1064716 | 0.75 | NPC1 (0.67) | NPC1RAB9AMAOBMAOAFFAR1 | |
| SCHEMBL20361216 | 0.75 | NPC1 (0.67) | NPC1RAB9AMAOBMAOAFFAR1 | |
| SCHEMBL25236433 | 0.74 | MAOB (0.54) | RAB9AMAOBMAOAFFAR1GPR84 | |
| SCHEMBL16493110 | 0.74 | MAPT (0.43) | CA12CA1CA9 | |
| SCHEMBL17265952 | 0.74 | MAPT (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312345-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | UNIV YALE (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240092759-A1 | Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use | UNIV YALE (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2024010585-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | YALE UNIVERSITY (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2022150584-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | YALE UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312345-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | ACE2, ACE, TMPRSS2 | NPC1 1455/4885RAB9A 3040/4885RHEB 3241/4885 |
| US-20240092759-A1 | Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use | ACE2, ACE, TMPRSS2 | NPC1 1051/4885RAB9A 2785/4885RHEB 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.